HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ISRG
Intuitive Surgical, Inc.
ISRG's fundamentals are strong and it looks cheap: trading at 53x earnings, below its usual 72x. Analysts expect strong earnings growth.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ISRG Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
ISRG's revenue, profitability, cash flow and balance sheet are all currently healthy.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ISRG PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 36x | $440 | — |
| Cheap | 52x | $429 | -2.5% |
| Current | 53x | $440 | — |
| Fair | 72x | $596 | +36% |
| Expensive | 84x | $691 | +57% |
Historical ranges are pointers, not guarantees.
ISRG's PE is in its cheap range at 53x. If earnings grow as analysts expect, today's price would be 36x next year's earnings.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ISRG Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Moderate | |
| High |
ISRG has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ISRG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $12.09 | +47% |
| Q3 2026 | $8.25 | +9% |
| Q2 2026 | $8.71 | +21% |
| Q1 2026 | $8.23 | +20% |
| Q4 2025 | $7.87 | +23% |
| Q3 2025 | $7.57 | +22% |
| Q2 2025 | $7.18 | +23% |
| Q1 2025 | $6.83 | +23% |
| Q4 2024 | $6.42 | +28% |
ISRG has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over ISRG on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
ISRG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $3B | +22% |
| Q2 2026 | $2.9B | +19% |
| Q1 2026 | $2.8B | +23% |
| Q4 2025 | $2.9B | +19% |
| Q3 2025 | $2.5B | +23% |
| Q2 2025 | $2.4B | +21% |
| Q1 2025 | $2.3B | +19% |
| Q4 2024 | $2.4B | +25% |
ISRG's revenue has grown year over year every quarter since late 2020: $3B last quarter, up 22% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 19% | -11 points |
| Q2 2026 | 34% | +3.1 points |
| Q1 2026 | 31% | +5.2 points |
| Q4 2025 | 30% | -0.3 points |
| Q3 2025 | 30% | +2 points |
| Q2 2025 | 30% | +2.2 points |
| Q1 2025 | 26% | +0.8 points |
| Q4 2024 | 30% | +7.1 points |
ISRG has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
ISRG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.1B | +51% |
| Q2 2026 | $948.4M | +69% |
| Q1 2026 | $808.6M | +74% |
| Q4 2025 | $730M | +43% |
| Q3 2025 | $735.6M | +60% |
| Q2 2025 | $560.1M | +80% |
| Q1 2025 | $465M | +1879% |
| Q4 2024 | $510.6M | +$717.8M |
ISRG has the edge over HIMS on cash flow, with more consistent year-over-year improvement.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ISRG on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ISRG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.6% | -5.7M shares |
| 1 year | -2.8% | -10.2M shares |
| 3 years | -1.8% | -6.6M shares |
| 5 years | -4.1% | -15.2M shares |
| Available history | -1.9% | -6.9M shares |
ISRG has 352M diluted shares, down 2.8% from a year ago, with $4.6B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3B |
| Q2 2026 | $320.3M |
| Q1 2026 | $1.1B |
| Q4 2025 | $201M |
| Q3 2025 | $1.9B |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
ISRG spent $4.6B buying back its own shares over the past year.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ISRG Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2021 | -0.6x | Net Cash |
| Q3 2021 | -0.6x | Net Cash |
| Q2 2021 | -0.9x | Net Cash |
| Q1 2021 | -1.0x | Net Cash |
| Q4 2020 | -1.2x | Net Cash |
| Q3 2020 | -1.1x | Net Cash |
| Q2 2020 | -1.5x | Net Cash |
| Q1 2020 | -0.8x | Net Cash |
ISRG has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ISRG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.7 | Neutral |
| Stochastic | 73.5 | Neutral |
ISRG's weekly RSI is 55 (neutral) and its Stochastic is 74 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ISRG PE vs Healthcare Sector
| Metric | ISRG | Sector median | Relative |
|---|---|---|---|
| PE | 53x | 26x | 106% above |
| PE % | 19 | 29 | 10 pts below |
ISRG is trading at 53x earnings, a 106% premium to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ISRG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $428.1 | 2.8% above |
| 20 week MA | $397.4 | 11% above |
| 50 week MA | $449.8 | 2.2% below |
| 100 week MA | $483.9 | 9.1% below |
| 200 week MA | $424.9 | 3.5% above |
ISRG has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
ISRG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $199.3 | $269.0 | +35% |
| 2021 | $269.0 | $363.9 | +35% |
| 2022 | $363.9 | $262.7 | -28% |
| 2023 | $262.7 | $337.4 | +28% |
| 2024 | $337.4 | $534.9 | +59% |
| 2025 | $534.9 | $577.8 | +8% |
| 2026 YTD | $577.8 | $439.9 | -24% |
ISRG has the edge over HIMS on returns for 2026, with the stronger performance.